AZELASTINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Azelastine, and when can generic versions of Azelastine launch?
Azelastine is a drug marketed by Alembic, Apotex, Epic Pharma Llc, Gland, Sandoz, Somerset Theraps Llc, Sun Pharm, Alkem Labs Ltd, Amneal, Apotex Inc, Aurobindo Pharma Ltd, Bionpharma, Hikma, Padagis Israel, Padagis Us, Sciegen Pharms, Zydus Pharms, Aurobindo Pharma, and Teva Pharms Usa Inc. and is included in thirty NDAs.
The generic ingredient in AZELASTINE is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azelastine
A generic version of AZELASTINE was approved as azelastine hydrochloride; fluticasone propionate by APOTEX on April 28th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZELASTINE?
- What are the global sales for AZELASTINE?
- What is Average Wholesale Price for AZELASTINE?
Summary for AZELASTINE
| US Patents: | 0 |
| Applicants: | 19 |
| NDAs: | 30 |
| Drug Prices: | Drug price information for AZELASTINE |
| Drug Sales Revenues: | Drug sales revenues for AZELASTINE |
| DailyMed Link: | AZELASTINE at DailyMed |



